 gastrin hypothesi implic antisecretori drug select newer potent long-act inhibitor acid secret proton pump inhibitor omeprazol avail gener use drug acid-pept diseas patient convent short-act antagonist safeti chronic administr drug question lifelong profound inhibit acid secret rat superpot inhibitor acid secret subtot fundectomi develop carcinoid tumor enterochromaffin-lik ecl cell gastric corpu avail evid role gastrin anim profound hypochlorhydria human hypergastrinem state zollinger-ellison syndrom atroph gastriti risk ecl-cel carcinoid tumor such observ concern human suscept tumor format respons potent inhibitor acid secret date case carcinoid tumor use omeprazol human achlorhydr dose signific hypergastrinemia effect treatment such measur risk ecl-cel carcinoid tumor human potent long-term antisecretori drug